The HIMS app was deployed on a smartphone in New York on February 12, 2025.
Gabby Jones | Bloomberg | Getty Images
Hims & Hers Health Shares rose 5% on Tuesday after the company announced that patients could access it Eli LilyWeight loss drugs Zepbound and diabetes drugs Moonjaro, as well as the common infusion of liraglutide, liraglutide, via its platform.
Zepbound, Mounjaro, and Liraglaltide are part of a class of weight loss drugs called GLP-1, and have exploded in popularity in recent years. Hims & Hers has launched a weight loss program Late 2023however, its GLP-1 offering has evolved as the company is fighting against a volatile supply and a regulated environment.
According to the HIMS & HERS website, Lily’s weekly infusion Zepbound and Mounjaro costs patients $1,899 a month. Generic lyraglutide costs $299 a month, but requires daily injections, Low effect More than other GLP-1 drugs.
“With our eyes ahead, we will continue to expand our offering of weight loss to provide an even more holistic and personalized experience,” said Dr. Craig Primack, Senior Vice President of Weight Loss at Hims & Hers. Blog post.
A spokesman for Lily said in a statement that the company “does not belong” to HIMS & HERS, and that Zepbound is available at a low cost for those with insured products or who purchase directly from the company.
In May, HIMS & HERS began prescribing complex Semaglutide, the active ingredient in Novo Nordisk’s GLP-1 weight loss drugs, and Wegovy. The offering was extremely popular and helped generate more than $225 million in revenue in 2024.
However, complex drugs can be traditionally mass-produced only in the presence of branded drug treatments Shortage. The US Food and Drug Administration announced in February that a shortage of semaglutide injected products had been resolved.
That meant that Hims & Hers had to significantly halt the provision of combined drugs, but some consumers may have access to personalized doses if clinically applicable.
In a company’s quarterly call with investors in February, HIMS & HERS said its weight loss offering consists primarily of oral medications and liraglutide. The company said it expects its weight loss offering to generate at least $725 million in annual revenue, excluding donations from compound semaglutide.
However, the company is still lobbying for combined drugs. When pop-ups on the HIMS & HERS website viewed by CNBC, users will “use your voice” and urge Congress and the FDA to maintain access to compounded treatments.
Tuesday’s rally saw HIMS and HERS shares rose about 27% in 2025 after rising 172% last year.
clock: HIMS & HERS stocks fall over concerns about weight loss business
